News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NC Research Campus Announces New Tenant, Angiogen


5/11/2007 1:35:04 PM

KANNAPOLIS, N.C, Angiogen, LLC will join the state-of-the-art North Carolina Research Campus, Vice President of Business Development Clyde Higgs announced today.

“We’re very happy to have Angiogen as a tenant at the NC Research Campus,” said Higgs. “We continue to reach out and find success with exciting companies like Angiogen in the medical devices, diagnostics, health and wellness and agri-bio tech fields.”

Angiogen’s mission is to develop novel oncology therapies, which will benefit those suffering from cancer. The company is preparing for a Phase I trial with its lead anti-angiogenesis drug, the Angiostatic Cocktail. Prior results in a short Phase I trial and in compassionate-use cases were very promising, with evidence of tumor regression and a decline in specific biomarkers. Angiogen was founded on the work of renowned scientist and physician Dr. Gerald A. Soff, an acknowledged expert in hematology and oncology. The Angiostatic Cocktail was developed at Northwestern University’s Feinberg School of Medicine.

“We are very happy to collaborate with the NC Research Campus. Our firm has the utmost respect for the truly groundbreaking and innovative approach espoused by Mr. David H. Murdock, Clyde Higgs, Lynne Scott Safrit and the rest of the team at the NC Research Campus,” said Mark Arizmendi, president and CEO of Angiogen. “We look forward to a long relationship with the NC Research Campus, the State of North Carolina and our shareholders. We feel that being located with other biotech entrepreneurs will be accretive for Angiogen and the other stakeholders in the park.”

At the NC Research Campus, Angiogen will create domicile its business operations and hopes to continue clinical research at the outstanding core lab facilities in Kannapolis.

Founded in 1998, Angiogen, based in Kannapolis, N.C. and Evanston, Ill. is the brainchild of Dr. Gerald A. Soff. The company has been funded by private investors and has collaborated with Genentech, Abbott Laboratories, Microbix and other pharmaceutical companies.

Plans for the NC Research Campus include:

· A 350-acre campus that complements North Carolina’s bustling biotech corridor.

· An initial 311,000-square-foot building to house the core laboratory, a state-of-the-art contract manufacturing biogenic facility and tenants. Campus partners broke ground on the building in February.

· One million square feet of office and lab space.

For more information about the NC Research Campus, please visit www.ncresearchcampus.net.


Read at BioSpace.com

comments powered by Disqus
Angiogen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES